Daily Stock Setups

Nippon Shinyaku signs agreement with Eli Lilly Japan and Eli Lilly and Company for Cialis

Posted on: Fri, 10 Apr 2009 14:45:00 EDT

Symbols: LLY, NPNKF

Are you looking to increase your ETF knowledge?

Apr 10, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
NPNKF | Quote | Chart | News | PowerRating -- Nippon Shinyaku Co., Ltd., a pharmaceutical company, Eli Lilly Japan K.K., and Eli Lilly and Company, a US-based pharmaceutical company, have signed a licensing agreement for Cialis (generic name: Tadalafil). Both Nippon Shinyaku and Eli Lilly Japan are based in Japan. Eli Lilly Japan K.K. is a subsidiary of Eli Lilly and Company.

Under the terms of the agreement, Cialis would be exclusively promoted and sold by Nippon Shinyaku in Japan starting July 1, 2009. Cialis was launched in Japan in September 2007 for the treatment of Erectile dysfunction (ED). Nippon Shinyaku would exclusively promote and sell Tadalafil's pulmonary arterial hypertension (PAH) indication after receiving regulatory and pricing and reimbursement approval. As for the benign prostatic hyperplasia (BPH) indication, Nippon Shinyaku and Eli Lilly Japan agree to co-market Tadalafil in Japan. Eli Lilly and Company would supply Cialis and other Tadalafil brands to be approved in the future to Nippon Shinyaku. Eli Lilly Japan would continue to retain Tadalafil manufacturing marketing licenses.

The two new Tadalafil indications are developing for pulmonary arterial hypertension and for urinary disorder caused by benign prostatic hyperplasia (BPH). As for the PAH indications, Eli Lilly Japan submitted its new drug application (NDA) to the Ministry of Health, Labor and Welfare (MHLW) in August, 2008, simultaneous to the US/EU NDA submissions. As for the BPH indications, the phase II global/domestic clinical trials are on going.

Deal Type    Partnership
Sub-Category Co-Marketing,Sales,Acquisition of Rights
Deal Status  Announced: 2009-04-09

Deal Participants

Partner 1 (Company) Nippon Shinyaku Co., Ltd.
Partner 2 (Company) Eli Lilly and Company
Partner 3 (Company) Eli Lilly Japan KK

Deal Rationale

This agreement would enhance Nippon Shinyaku's urology product line-up.

For full details on Eli Lilly & Company (LLY) LLY. Eli Lilly & Company (LLY) has Short Term PowerRatings at TradingMarkets. Details on Eli Lilly & Company (LLY) Short Term PowerRatings is available at This Link.

For full details on (NPNKF) NPNKF. (NPNKF) has Short Term PowerRatings at TradingMarkets. Details on (NPNKF) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.